Mount Sinai scientists recognized with Global AI Prize for novel Alzheimer’s disease research platform
Grant and Award Announcement
In honor of Alzheimer's Awareness Month, we’re exploring the science and stories surrounding Alzheimer’s disease.
Updates every hour. Last Updated: 21-Jun-2026 17:15 ET (21-Jun-2026 21:15 GMT/UTC)
A team led by Dr. Kuan-lin Huang, PhD, has been named a winner of the $1 million Alzheimer’s Insights AI Prize, the Alzheimer’s Disease Data Initiative (AD Data Initiative) announced on March 20. Dr. Huang is an Associate Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. The award honors the development of Biomni-AD, an advanced AI-powered “co-scientist” designed to dramatically reduce the time required to generate scientific insights from complex biomedical data. The Mount Sinai team collaborated with partners at Stanford University on the winning project. Originally conceived as a single $1 million award, the competition expanded to recognize two winning teams, doubling the total prize amount to $2 million—reflecting both the exceptional quality of submissions and the urgency of advancing new approaches to Alzheimer’s disease and related dementias.
A 2025 study conducted by researchers from the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy PAS, Wroclaw Medical University and the University of Connecticut shows that oral health, immune function and cognitive decline are closely interconnected in Alzheimer’s disease. The findings contribute to the growing concept of the mouth–brain axis, suggesting that even mild, chronic inflammation of the gums may have systemic consequences. The study demonstrated that patients with Alzheimer’s disease not only present worse oral hygiene and increased gingival inflammation, but also exhibit significant dysregulation of the immune system, characterized by reduced baseline activity alongside an exaggerated response to bacterial stimulation. This imbalance may reflect both immune exhaustion and hyperreactivity, which together can contribute to harmful inflammatory processes. Importantly, the severity of gingival inflammation was associated with lower cognitive test scores, regardless of age or sex, indicating a direct relationship between oral health and cognitive performance. The proposed mechanism suggests that chronic periodontal inflammation places a continuous burden on the immune system, leading to its dysfunction and facilitating the penetration of inflammatory signals into the brain, where they may enhance neuroinflammation and accelerate disease progression. The study also highlights a practical challenge, as individuals with Alzheimer’s disease tend to neglect daily oral hygiene, which further exacerbates the problem. These results underline that oral health should be considered an integral part of systemic health and dementia care, and that simple preventive measures, such as maintaining proper oral hygiene and supporting patients through caregiver involvement, may have meaningful implications for brain health.
By the age of 40, approximately 95% of people with Down syndrome develop Alzheimer’s disease, the leading cause of death for this population. Yet individuals with Down syndrome historically have been excluded from participating in clinical trials into treatments for Alzheimer’s disease. Now, that access will expand in the U.S. and globally, thanks to a game-changing gift from the Linda and Mike Mussallem Foundation to the Keck School of Medicine of USC and its Epstein Family Alzheimer’s Therapeutic Research Institute (Epstein ATRI). The Mussallem Foundation gift will add more domestic sites to the ACTC-DS clinical trial network, currently 20 sites strong. The funding will also maintain four international clinical trial sites that would have paused research due to a loss of government funding, at Trinity Centre for Ageing and Intellectual Disability, Dublin; University of Cambridge, United Kingdom; Institut Jérôme Lejeune, Paris; and, Sant Pau Medical Research Institute, Barcelona. The Mussallem’s generous gift includes a matching component that will effectively double the impact of their support, accelerating the enhancement and expansion of the ACTC-DS network.
An expansive clinical trial led by University of South Florida researchers and aimed at delaying the onset of dementia continues to receive major federal support with an additional $2.8 million from the National Institutes of Health. The funding helps to continue research into whether computerized brain training exercises can reduce the risk of cognitive impairment and dementia such as Alzheimer’s disease. The Preventing Alzheimer’s with Cognitive Training (PACT) study has now received more than $50 million in federal grant funding.